PROKIDNEY CORP CLASS A (PROK)
Health Care · Regenerative medicine / cell therapy · NASDAQ
ProKidney is pioneering a first-in-class autologous kidney cell therapy to slow kidney function decline in advanced CKD and diabetes patients, currently in Phase 3 trials with FDA RMAT designation.
What PROKIDNEY CORP CLASS A does
ProKidney is a late-stage clinical biotechnology company developing rilparencel, an autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes. The product uses a patient's own selected renal cells (SRC) expanded and reinjected into the kidneys via minimally invasive outpatient procedure, eliminating the need for immunosuppressive therapy required in transplants. The company is currently conducting a Phase 3 clinical trial (REGEN-006/PROACT 1) targeting patients with Stage 4 CKD and late Stage 3b CKD, with topline data expected in Q2 2027.
Themes: ["regenerative medicine","cell therapy","chronic kidney disease","diabetes complications","FDA RMAT designation"]
Fundamentals
- Price$1.80 as of 2026-07-09 close
- Market cap$544M as of 2026-07-10
- 1-year return-58.5% as of 2026-07-09 close
- Net margin-8131.5% as of 2026-07-10
- ROE-28.1% as of 2026-07-10
- Debt / equity5.40 as of 2026-07-10
- Revenue growth (YoY)+190.5% as of 2026-07-10
- Beta1.79 as of 2026-07-10
Key risks (from latest filing)
["Phase 3 clinical development dependency — rilparencel remains unproven in late-stage trials with efficacy and safety readouts not expected until 2027–2029, creating significant execution and regulatory approval risk","Massive cash burn with net margin of -8131.5% and operating losses of ~$45M in Q1 2026 versus minimal revenue of $226K, requiring additional capital raises to fund ongoing development","Personalized autologous cell therapy manufacturing complexity — each patient requires custom biopsy processing and cell preparation, creating scalability, quality control, and operational challenges if approved"]
Competitors & peers
- Organogenesis Holdings (ORGO)
- Fresenius Medical Care (FMS)
- DaVita Inc. (DVA)
- Renal Solutions (private)
- Miromatrix Medical Inc. (private)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.